BARCLAYS PLC

Barclays faces a possible 3‑5% windfall tax and reveals strategic 1‑1.3% holdings in key UK firms, urging investors to reassess earnings and capital plans amid new regulatory pressures.

Barclays’ latest RNS reveals strategic stakes in Easyjet, Advanced Medical Solutions and a Prologis hedge—showing a risk‑managed, dividend‑focused approach with upside potential for investors.

Barclays discloses 1%+ holdings in Segro, DCC Energy, Tate & Lyle, and EasyJet, showing a diversified, derivative‑backed strategy boosting confidence in its 2026 performance.

Barclays’ flat third‑quarter trading revenue sparks a sector‑wide rethink on banking profitability, highlighting risks, regulatory pressures and tech‑driven strategy.

Barclays’ 100‑million‑share buyback cuts capital, boosts EPS, and reflects confidence amid U.S. Fed uncertainty and global liquidity shifts.

Barclays reveals strategic equity & derivative holdings in TSB, Prologis, and health‑care firms, showcasing targeted growth, risk hedging, and portfolio diversification.

Barclays’ shift to Chinese equity derivatives shows a bullish trend, but hidden volatility risks and potential conflicts of interest demand careful scrutiny.

Barclays doubles its Singapore private‑banking workforce amid growth ambitions, but forensic reviews reveal cost‑driven expansion, hefty shareholdings, and leadership turbulence, urging stakeholders to scrutinize the bank’s true impact.

Explore how Barclays PLC’s 2026 Fed rate forecast and UK regulatory changes may impact borrowers, investors, and the broader economy—and what transparency gaps still exist.

Barclays’ latest stock move shows how Fed policy, yield‑curve shifts, and geopolitical tensions shape its NIM and credit risk, while digital growth offers a hedge.